Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$5.87
+$0.25 · +4.45%
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Previous close
$5.87
+$0.25 · +4.45%
After-hours
$5.82
−$0.05 · -0.85%
Sep 14, 7:30 PM ET
Regular session · ET · Market data may be delayed.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Day range
Current $5.87
52-week range
Current $5.87
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
52
Mixed
Risk
62
High Risk
Momentum
77
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Day range
Current $5.87
52-week range
Current $5.87
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 1.85M USD | 3.19M USD | 5M USD | 6.55M USD | 5.48M USD |
| Selling, general, and administrative | 3.91M USD | 7.63M USD | 5.52M USD | 6.6M USD | 6.02M USD |
| Operating expenses | 5.76M USD | 10.82M USD | 10.52M USD | 13.16M USD | 11.5M USD |
| Interest expense | — | — | — | 21.53K USD | — |
| Depreciation and amortization | 157.29K USD | 206.17K USD | 275.45K USD | 234.26K USD | 224.42K USD |
| Operating income | −5.76M USD | −10.82M USD | −10.52M USD | −13.16M USD | −11.5M USD |
| Net income | −7.03M USD | −11.51M USD | −10.06M USD | −13.18M USD | −11.23M USD |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 7, 2024 | 1:35 | — | — |
Stock split | Aug 20, 2024 | 1:50 | — | — |
Stock split | Dec 9, 2022 | 1:20 | — | — |
Effective Nov 7, 2024
1:35
Effective Aug 20, 2024
1:50
Effective Dec 9, 2022
1:20
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
